Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
CBM's Cash-to-Debt is ranked higher than
99% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. CBM: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CBM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.21 Max: No Debt
Current: No Debt
0
No Debt
Equity-to-Asset 0.74
CBM's Equity-to-Asset is ranked higher than
58% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBM: 0.74 )
Ranked among companies with meaningful Equity-to-Asset only.
CBM' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.48 Max: 0.75
Current: 0.74
0.22
0.75
Interest Coverage 136.50
CBM's Interest Coverage is ranked lower than
71% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBM: 136.50 )
Ranked among companies with meaningful Interest Coverage only.
CBM' s Interest Coverage Range Over the Past 10 Years
Min: 5.13  Med: 17.35 Max: 180.63
Current: 136.5
5.13
180.63
Piotroski F-Score: 6
Altman Z-Score: 7.15
Beneish M-Score: -2.87
WACC vs ROIC
15.77%
29.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 25.58
CBM's Operating Margin % is ranked higher than
91% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. CBM: 25.58 )
Ranked among companies with meaningful Operating Margin % only.
CBM' s Operating Margin % Range Over the Past 10 Years
Min: 9.32  Med: 13.52 Max: 26.7
Current: 25.58
9.32
26.7
Net Margin % 18.69
CBM's Net Margin % is ranked higher than
87% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. CBM: 18.69 )
Ranked among companies with meaningful Net Margin % only.
CBM' s Net Margin % Range Over the Past 10 Years
Min: 3.18  Med: 10.67 Max: 22.53
Current: 18.69
3.18
22.53
ROE % 21.02
CBM's ROE % is ranked higher than
94% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. CBM: 21.02 )
Ranked among companies with meaningful ROE % only.
CBM' s ROE % Range Over the Past 10 Years
Min: 8.97  Med: 17.12 Max: 47.26
Current: 21.02
8.97
47.26
ROA % 15.08
CBM's ROA % is ranked higher than
95% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. CBM: 15.08 )
Ranked among companies with meaningful ROA % only.
CBM' s ROA % Range Over the Past 10 Years
Min: 2.22  Med: 8.84 Max: 17.1
Current: 15.08
2.22
17.1
ROC (Joel Greenblatt) % 36.20
CBM's ROC (Joel Greenblatt) % is ranked higher than
90% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. CBM: 36.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CBM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 9.74  Med: 20.04 Max: 40.41
Current: 36.2
9.74
40.41
3-Year Revenue Growth Rate 10.50
CBM's 3-Year Revenue Growth Rate is ranked higher than
61% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CBM: 10.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CBM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -18.1  Med: 4.5 Max: 16
Current: 10.5
-18.1
16
3-Year EBITDA Growth Rate 26.20
CBM's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CBM: 26.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CBM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -26.4  Med: 12 Max: 113
Current: 26.2
-26.4
113
3-Year EPS without NRI Growth Rate 19.00
CBM's 3-Year EPS without NRI Growth Rate is ranked higher than
70% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CBM: 19.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CBM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 16.5 Max: 302.1
Current: 19
0
302.1
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CBM's 30-Y Financials

Financials (Next Earnings Date: 2018-08-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

CBM Guru Trades in Q2 2017

Columbia Wanger 833,486 sh (+470.58%)
Jim Simons 254,202 sh (+32.53%)
Jeremy Grantham 4,400 sh (unchged)
Joel Greenblatt Sold Out
Third Avenue Management 68,885 sh (-19.42%)
Chuck Royce 61,598 sh (-48.50%)
» More
Q3 2017

CBM Guru Trades in Q3 2017

Paul Tudor Jones 10,249 sh (New)
Columbia Wanger 1,138,170 sh (+36.56%)
Jeremy Grantham Sold Out
Third Avenue Management 63,085 sh (-8.42%)
Chuck Royce 43,500 sh (-29.38%)
Jim Simons 161,500 sh (-36.47%)
» More
Q4 2017

CBM Guru Trades in Q4 2017

Chuck Royce 89,511 sh (+105.77%)
Columbia Wanger 1,234,965 sh (+8.50%)
Third Avenue Management Sold Out
Jim Simons 157,300 sh (-2.60%)
Paul Tudor Jones 6,441 sh (-37.15%)
» More
Q1 2018

CBM Guru Trades in Q1 2018

Steven Cohen 83,045 sh (New)
Joel Greenblatt 85,908 sh (New)
Paul Tudor Jones 20,535 sh (+218.82%)
Jim Simons Sold Out
Chuck Royce 67,768 sh (-24.29%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:CBM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2018-03-31 New Buy0.06%$48 - $57 $ 46.55-13%85,908
Third Avenue Management 2017-12-31 Sold Out 0.16%$42.65 - $56.3 $ 46.55-6%0
Third Avenue Management 2017-09-30 Reduce -8.42%0.02%$49.85 - $61.95 $ 46.55-16%63,085
Third Avenue Management 2017-06-30 Reduce -19.42%0.04%$51.4 - $60.9 $ 46.55-17%68,885
Joel Greenblatt 2017-06-30 Sold Out 0.02%$51.4 - $60.9 $ 46.55-17%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2834
Compare:NAS:AIMT, BOM:539268, NAS:ENTA, HKSE:06826, NAS:MYOK, NAS:INSM, NAS:DNLI, NAS:ESPR, SZSE:002030, NAS:XLRN, NAS:ARNA, NAS:CORT, NAS:SPPI, NAS:MDGL, NAS:ACAD, NAS:ATRA, NAS:RGEN, NAS:ICPT, XKRX:005250, OSTO:VITR » details
Traded in other countries:XBX.Germany,
Headquarter Location:USA
Cambrex Corp is a biotechnology company focused on developing and commercializing new and generic therapeutics. It provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics.

Cambrex is a biotechnology company focused on developing and commercializing new and generic therapeutics. The company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. Cambrex's portfolio growth strategy has a particular focus on the later stages of the clinical trial process. It also works to secure long-term supply agreements to produce active pharmaceutical ingredients and intermediates for newly approved drug products. Additionally, Cambrex sometimes works with partners to codevelop portfolios of niche generic drug products in finished dosage form.

Ratios

vs
industry
vs
history
PE Ratio 14.61
CBM's PE Ratio is ranked higher than
71% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. CBM: 14.61 )
Ranked among companies with meaningful PE Ratio only.
CBM' s PE Ratio Range Over the Past 10 Years
Min: 1.05  Med: 16.58 Max: 59.25
Current: 14.61
1.05
59.25
Forward PE Ratio 14.22
CBM's Forward PE Ratio is ranked higher than
63% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. CBM: 14.22 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 14.61
CBM's PE Ratio without NRI is ranked higher than
73% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. CBM: 14.61 )
Ranked among companies with meaningful PE Ratio without NRI only.
CBM' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.27  Med: 16.81 Max: 94.8
Current: 14.61
5.27
94.8
Price-to-Owner-Earnings 20.24
CBM's Price-to-Owner-Earnings is ranked higher than
70% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. CBM: 20.24 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CBM' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.29  Med: 21.97 Max: 364.38
Current: 20.24
1.29
364.38
PB Ratio 2.70
CBM's PB Ratio is ranked higher than
61% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CBM: 2.70 )
Ranked among companies with meaningful PB Ratio only.
CBM' s PB Ratio Range Over the Past 10 Years
Min: 0.61  Med: 2.49 Max: 5.9
Current: 2.7
0.61
5.9
PS Ratio 2.74
CBM's PS Ratio is ranked higher than
78% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 2.74 )
Ranked among companies with meaningful PS Ratio only.
CBM' s PS Ratio Range Over the Past 10 Years
Min: 0.18  Med: 1.37 Max: 4.26
Current: 2.74
0.18
4.26
Price-to-Free-Cash-Flow 21.20
CBM's Price-to-Free-Cash-Flow is ranked higher than
67% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. CBM: 21.20 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CBM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.87  Med: 17.37 Max: 74.45
Current: 21.2
4.87
74.45
Price-to-Operating-Cash-Flow 11.35
CBM's Price-to-Operating-Cash-Flow is ranked higher than
79% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. CBM: 11.35 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CBM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.92  Med: 10.96 Max: 63.93
Current: 11.35
2.92
63.93
EV-to-EBIT 9.23
CBM's EV-to-EBIT is ranked higher than
76% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. CBM: 9.23 )
Ranked among companies with meaningful EV-to-EBIT only.
CBM' s EV-to-EBIT Range Over the Past 10 Years
Min: -146.1  Med: 11.7 Max: 20.2
Current: 9.23
-146.1
20.2
EV-to-EBITDA 7.53
CBM's EV-to-EBITDA is ranked higher than
78% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. CBM: 7.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBM' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.7  Med: 8.3 Max: 26.6
Current: 7.53
3.7
26.6
EV-to-Revenue 2.36
CBM's EV-to-Revenue is ranked higher than
83% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. CBM: 2.36 )
Ranked among companies with meaningful EV-to-Revenue only.
CBM' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.6  Med: 1.5 Max: 4.2
Current: 2.36
0.6
4.2
PEG Ratio 0.58
CBM's PEG Ratio is ranked higher than
84% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. CBM: 0.58 )
Ranked among companies with meaningful PEG Ratio only.
CBM' s PEG Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.1 Max: 13
Current: 0.58
0.47
13
Shiller PE Ratio 31.57
CBM's Shiller PE Ratio is ranked higher than
59% of the 79 Companies
in the Global Biotechnology industry.

( Industry Median: 44.16 vs. CBM: 31.57 )
Ranked among companies with meaningful Shiller PE Ratio only.
CBM' s Shiller PE Ratio Range Over the Past 10 Years
Min: 2.78  Med: 31.71 Max: 326.5
Current: 31.57
2.78
326.5
Current Ratio 5.04
CBM's Current Ratio is ranked higher than
57% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. CBM: 5.04 )
Ranked among companies with meaningful Current Ratio only.
CBM' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.62 Max: 5.19
Current: 5.04
0.9
5.19
Quick Ratio 3.90
CBM's Quick Ratio is ranked lower than
53% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. CBM: 3.90 )
Ranked among companies with meaningful Quick Ratio only.
CBM' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.43 Max: 4.55
Current: 3.9
0.5
4.55
Days Inventory 155.38
CBM's Days Inventory is ranked lower than
67% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. CBM: 155.38 )
Ranked among companies with meaningful Days Inventory only.
CBM' s Days Inventory Range Over the Past 10 Years
Min: 124.14  Med: 134.64 Max: 156.93
Current: 155.38
124.14
156.93
Days Sales Outstanding 35.29
CBM's Days Sales Outstanding is ranked higher than
61% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. CBM: 35.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.29  Med: 59.82 Max: 82.29
Current: 35.29
35.29
82.29
Days Payable 47.66
CBM's Days Payable is ranked lower than
60% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. CBM: 47.66 )
Ranked among companies with meaningful Days Payable only.
CBM' s Days Payable Range Over the Past 10 Years
Min: 37.86  Med: 46.83 Max: 63.55
Current: 47.66
37.86
63.55

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.80
CBM's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CBM: -1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15.9  Med: -1.7 Max: 5.1
Current: -1.8
-15.9
5.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 6.17
CBM's Price-to-Net-Current-Asset-Value is ranked lower than
51% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. CBM: 6.17 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CBM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.29  Med: 7.68 Max: 107.17
Current: 6.17
1.29
107.17
Price-to-Tangible-Book 2.99
CBM's Price-to-Tangible-Book is ranked higher than
65% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. CBM: 2.99 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CBM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.33  Med: 3.39 Max: 14.12
Current: 2.99
0.33
14.12
Price-to-Intrinsic-Value-Projected-FCF 1.44
CBM's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. CBM: 1.44 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CBM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.7  Med: 2.01 Max: 46.39
Current: 1.44
0.7
46.39
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.36
CBM's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
53% of the 30 Companies
in the Global Biotechnology industry.

( Industry Median: 1.64 vs. CBM: 1.36 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
CBM' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.31  Med: 1.82 Max: 2.59
Current: 1.36
1.31
2.59
Price-to-Median-PS-Value 2.01
CBM's Price-to-Median-PS-Value is ranked lower than
86% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. CBM: 2.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CBM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.93 Max: 6.81
Current: 2.01
0.11
6.81
Price-to-Peter-Lynch-Fair-Value 0.58
CBM's Price-to-Peter-Lynch-Fair-Value is ranked higher than
89% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. CBM: 0.58 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CBM' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.49  Med: 1.04 Max: 8.25
Current: 0.58
0.49
8.25
Price-to-Graham-Number 1.39
CBM's Price-to-Graham-Number is ranked higher than
73% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.76 vs. CBM: 1.39 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CBM' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.36  Med: 1.51 Max: 4.29
Current: 1.39
0.36
4.29
Earnings Yield (Greenblatt) % 10.86
CBM's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. CBM: 10.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CBM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.6  Med: 8.3 Max: 14.8
Current: 10.86
-1.6
14.8
Forward Rate of Return (Yacktman) % 22.84
CBM's Forward Rate of Return (Yacktman) % is ranked higher than
86% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 12.87 vs. CBM: 22.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CBM' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -35  Med: 11.5 Max: 22.84
Current: 22.84
-35
22.84

More Statistics

Revenue (TTM) (Mil) $570.55
EPS (TTM) $ 3.19
Beta2.14
Volatility41.32%
52-Week Range $42.55 - 62.30
Shares Outstanding (Mil)32.96

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 572 608
EBIT (Mil $)
EBITDA (Mil $) 178 184
EPS ($) 3.28 3.55
EPS without NRI ($) 3.28 3.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}